Aduro BioTech, Inc. has entered an agreement granting Janssen Biotech an exclusive, worldwide license to certain product candidates for the treatment of prostate cancer based on its LADD immunotherapy platform.   Aduro is eligible to receive as much as $365 million in upfront license fees and milestone payments based on development, regulatory and commercialization milestones, should multiple programs advance to commercialization, as well as royalties on sales.   Janssen will be responsible for ...